+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
APLLTD

Alembic Pharmaceuticals Share Price

₹830.10 -4.35 (-0.52%)
30.56% Gain from 52W Low

07 Aug, 2026 3:59 PM (IST)

Alembic Pharmaceuticals live price: ₹830.10. It opened at ₹835 vs previous close ₹834; intraday high/low: ₹852/₹826. The 50 & 200 DMA stand at ₹798.60/₹808.20.

Alembic Pharmaceuticals Performance

  • Today's Low
  • ₹826
  • Today's High
  • ₹852
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹1,002
  • Open Price₹835
  • Previous Close₹834
  • Volume170,120
  • 50 DMA₹798.60
  • 100 DMA₹788.40
  • 200 DMA₹808.20

Alembic Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -0.66%
  • Over 3 Month + 5.68%
  • Over 6 Month + 4.07%
  • Over 1 Year -12.46%

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Invest Now

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.5
  • PEG Ratio
  • 1.6
  • Market Cap Cr
  • 16,317
  • P/B Ratio
  • 2.9
  • Average True Range
  • 22.8
  • EPS
  • 35.3
  • Dividend Yield
  • 1.4
  • MACD Signal
  • 5.6
  • RSI
  • 57.09
  • MFI
  • 77.22

Latest Stock News Updates

Alembic Pharmaceuticals Ltd - 533573 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Please find attached herewith the Scrutinizer Report and Voting Results of the AGM held on 5th August, 2026.

Alembic Pharmaceuticals Ltd - 533573 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Please find attached Proceedings of AGM held on 5th August, 2026.

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find attached herewith the Newspaper Advertisement.

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹830.10
-4.35 (-0.52%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹815.00
  • 50 Day
  • ₹798.60
  • 100 Day
  • ₹788.40
  • 200 Day
  • ₹808.20

Resistance and Support

835.8 Pivot Speed
  • R3 872.50
  • R2 862.20
  • R1 846.10
  • S1 819.80
  • S2 809.50
  • S3 793.40

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-04 Quarterly Results
2026-05-15 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-04 Quarterly Results & Others To consider other business matters.
2025-08-05 Quarterly Results & Others To consider other business matters.
Date Purpose Remarks
2026-07-29 FINAL Rs.12.00 per share(600%)Final Dividend
2025-07-29 FINAL Rs.11.00 per share(550%)Final Dividend
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)
View Alembic Pharmaceuticals Dividend History Arrow

Alembic Pharmaceuticals Shareholding Pattern

69.87%
10%
8.73%
7.2%
4.17%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. View More
  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • ISIN
  • INE901L01018

Similar Stocks to Alembic Pharmaceuticals

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹830 As on 07 August, 2026 | 19:22

The Market Cap of Alembic Pharmaceuticals is ₹16316.7 Cr As on 07 August, 2026 | 19:22

The P/E ratio of Alembic Pharmaceuticals is 23.5 As on 07 August, 2026 | 19:22

The PB ratio of Alembic Pharmaceuticals is 2.9 As on 07 August, 2026 | 19:22

The 52 week High & Low of Alembic Pharmaceuticals is ₹1002/₹635.8 respectively As on 07 August, 2026 | 19:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23